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Abstract  24 
Background 25 
Arboviruses are an emerging group of viruses that are causing increasing health concerns 26 
globally, including in Europe. Clinical presentation usually consists of a non-specific febrile 27 
illness that may be accompanied by rash, arthralgia and arthritis and/or with neurological or 28 
haemorrhagic syndromes. The range of differential diagnoses of other infectious and non-29 
infectious aetiologies is broad, presenting a challenge for physicians. While knowledge of the 30 
geographic distribution of pathogens and the current epidemiological situation, incubation 31 
periods, exposure risk factors and vaccination history can help guide the diagnostic 32 
approach, the non-specific and variable clinical presentation can delay final diagnosis. 33 
Aims and Sources  34 
This narrative review aims to summarize the main clinical and laboratory-based findings of 35 
the three most common imported arboviruses in Europe. Evidence is extracted from 36 
published literature and clinical expertise of European arbovirus experts. 37 
Content 38 
We present three cases that highlight similarities and differences between some of the most 39 
common travel-related arboviruses imported to Europe. These include a patient with 40 
chikungunya virus infection presenting in Greece, a case of dengue fever in Turkey, and a 41 
travel-related case of Zika virus infection in Romania. 42 
Implications 43 
Early diagnosis of travel-imported cases is important to reduce the risk of localized outbreaks 44 
of tropical arboviruses such as dengue and chikungunya and the risk of local transmission 45 
from body fluids or vertical transmission. 46 
Given the global relevance of arboviruses and the continuous risk of (re-)emerging arbovirus 47 
events, clinicians should be aware of the clinical syndromes of arbovirus fevers and the 48 
potential pitfalls in diagnosis. 49 
 50 
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Introduction 53 
With an increase in global travel rising to around 950 million persons per year, physicians are 54 
frequently confronted with patients potentially infected with exotic pathogens (1). Besides 55 
malaria, infection with an arbovirus is a common cause of fever in travellers returning to 56 
Europe (2). Arboviruses are a large group of emerging RNA viruses spanning different viral 57 
families and genera that are responsible for human disease worldwide in the range of 58 
hundreds of million cases annually (3-5). 59 
In Europe, several endemic arboviruses are of clinical importance such as tick-borne 60 
encephalitis, West Nile fever, Crimean-Congo haemorrhagic fever and sandfly fever (6). 61 
However, there is heterogeneity in the surveillance of endemic, well-known arboviruses and 62 
uncertainty about the true burden of related illness in Europe (6). The situation is aggravated 63 
by (re-)introduction of vectors as well as introduction of viraemic patients following travel (5-64 
8). Limited autochthonous outbreaks have been described for dengue (DENV) (9-13) and 65 
chikungunya (CHIKV) virus in Europe (14-16). The endemic areas for DENV and CHIKV are 66 
found in tropical and subtropical regions of the world. DENV is the most successful arbovirus 67 
in terms of emergence in recent decades, with an estimated 390 million infections per year 68 
globally (17). The main endemic areas are in Asia and South America with less data in some 69 
areas, particularly in Africa. Returning travellers presenting with DENV can serve as 70 
“sentinels” and a recent study estimated the proportion of cases in Africa to be in the same 71 
range as in Latin America (17-19). CHIKV is mainly found in Asia and Africa, with recent 72 
large outbreaks on the Indian Ocean islands and spread to the New World, particularly the 73 
Caribbean and the Americas (20-22). 74 
 Zika virus was considered to be a flavivirus of low interest, until its dramatic emergence in 75 
French Polynesia in 2013 and subsequently in South America in 2015. While Zika usually 76 
causes mild disease in adults, it can lead to congenital malformations when infecting 77 
pregnant women and is also associated with Guillain-Barré syndrome (23). This has led to 78 
increased awareness of the potential risk of other neglected arboviruses (5). Fortunately, no 79 
vector-borne transmission of Zika virus has been recorded in Europe to date (6). However, 80 
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sexual transmission of Zika virus has been reported and is an additional source of 81 
introduction besides vectors and diseased travellers (24, 25). 82 
While dengue, Zika and chikungunya account for the vast majority of travel-imported 83 
arbovirus cases in Europe, there is a plethora of other, less well-known arboviruses capable 84 
of causing human disease. These include viruses such as Jamestown Canyon, Mayaro, 85 
Oropouche, Tahyna, and Usutu viruses and many more, which are not known to most 86 
clinicians (26-28). The increasing importance of arboviruses in Australia, such as Kunjin 87 
virus, Murray Valley fever and Ross River fever poses an under-recognized hazard for 88 
travellers from Europe (29, 30). 89 
For clinicians, the diagnosis of travellers presenting with syndromes of fever, rash, myalgia, 90 
arthralgia and headache is challenging, due to their non-specific nature and the wide range 91 
of potential differential diagnoses. Diagnostic test strategies for arboviruses can be complex 92 
due to the short viraemic period, pitfalls in serology such as high levels of antibody cross-93 
reactivity, and patchy access to specialized arbovirus diagnostics. Despite similarities in the 94 
disease presentations, there are differences which, together with travel and vaccination 95 
history, can help guide the identification, sampling and differential diagnostics. 96 
We present three cases to highlight the difficulties which European clinicians face in 97 
recognizing travel-related imported arbovirus illnesses and we discuss similarities and 98 
differences in clinical and laboratory findings.  99 
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Imported arbovirus infections to Europe 100 
Case 1: An imported chikungunya case to Greece 101 
In the spring of 2016, a woman in her twenties returned to Greece from Recife, Brazil, where 102 
she had stayed since November 2015. During her return travel she developed myalgia and 103 
arthralgia for 9 days followed by development of high fever (40°C) and mild headache upon 104 
arriving in Greece. There was no significant past medical or surgical history. On physical 105 
examination there was no rash, hepatosplenomegaly or conjunctivitis, but she had swelling 106 
of both knees and the left wrist. Her white blood cell count was 3.2 x 109/L with 50% 107 
neutrophils, 34% lymphocytes and 13% monocytes, haematocrit 39.5%, platelet count 247 x 108 
109/L, and C-reactive protein 10 mg/dL (normal <5). All other tests were unremarkable. Her 109 
fever subsided over the following 72 hours, with normalization of her laboratory tests and she 110 
was discharged after 3 days of hospitalization. She was advised to adopt safe sex practices 111 
until results for ZIKV were received.  112 
Molecular testing for DENV, ZIKV and CHIKV was performed at the National Reference 113 
Centre for Arboviruses in Greece on the samples taken on the 2nd day of illness using 114 
commercial Real Time RT-PCR kits (Altona Diagnostics GmbH, Hamburg, DE). CHIKV RNA 115 
was detected in serum and blood. An in-house RT-nested PCR using generic alphavirus 116 
primers (31) obtained a sequence clustering in the ESCA genotype. The sequence showed 117 
100% identity to sequences from Brazil (32). The presence of CHIKV IgM and IgG antibodies 118 
was tested using indirect immunofluorescence test and ELISA, respectively (Euroimmune, 119 
Lübeck, DE). A weak positive result was obtained only for CHIKV IgM antibodies in the initial 120 
sera, while both IgM and IgG antibodies were detected in a convalescent sample taken on 121 
March 1. Serology for DENV and ZIKV remained negative. CHIKV was isolated from her 122 
blood in Vero E6 cells, with cytopathic effects seen on the 2nd day after inoculation. The 123 
patient had an unremarkable recovery, however arthralgia persisted for 3 more months. 124 
 125 
Case 2: An imported dengue fever case in Turkey 126 
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A 24-year-old French national presented in November 2017 at the Koç University Hospital, 127 
Istanbul with a three-day history of fever, fatigue and malaise, starting four days after 128 
returning from a nine-month residence in Cambodia.  129 
On admission, his temperature was 38.9 °C, his blood pressure was 130/70 mmHg and he 130 
had a right subconjunctival haemorrhage. No rash or hepatosplenomegaly was detected and 131 
other physical examination findings were normal. Laboratory tests revealed a total white cell 132 
count of 3.65 x 109/L (normal 4.4-11.5), platelet count 176 x 109/L (normal range 100-400), 133 
mildly elevated AST with peak level 100 U/L (normal range 0-31), ALT peak 67 U/L (normal 134 
range 0-31), LDH peak 200 U/L (normal range 135-225) and GGT peak 244 U/L (normal 135 
range 8-61), CRP peak 27.6 mg/L (normal range 0-5). A further tropical diagnostic workup 136 
was requested and blood samples taken on 2 of hospitalization (day 5 of illness) were sent to 137 
the Public Health Institute of Turkey, Ankara. On the 3rd day of hospitalization he became 138 
afebrile but his temperature increased again 2 days later. Dengue IgG and IgM antibodies 139 
(Immunofluorescence test, Euroimmune) and PCR (Reverse transcriptase PCR, Multiplex) 140 
were positive, confirming acute dengue infection. He was discharged on the 7th day of 141 
hospitalization (day 12 of illness) and had made a full recovery with normalization of blood 142 
tests at outpatient review on day 14 of illness. Paired serology remained negative for 143 
leptospirosis. 144 
 145 
Case 3: An imported Zika virus case in Romania 146 
A man in his thirties presented in the summer of  2016 at the University Hospital of Infectious 147 
Diseases, Cluj-Napoca, Romania with a 4-day history of fever, headache, fatigue, myalgia 148 
and rash spreading from the neck and thorax before becoming generalized. Symptoms 149 
started 5 days after he left the Dominican Republic, where he had stayed for seven days.  150 
On physical examination, his temperature was 36.8°C  and he had conjunctivitis of the right 151 
eye, a generalized non-pruritic macular rash and diffuse erythematous pharyngitis. There 152 
were no other significant findings. Laboratory tests revealed mild thrombocytopenia of 135 x 153 
109/L (normal range 150-450), with normal haemoglobin, inflammatory markers and renal 154 
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and liver biochemical parameters. Malaria was ruled out by rapid diagnostic test (Malaria 155 
MBPan Mascia Brunelli) and thin and thick blood film examinations. Urinalysis, blood cultures 156 
and viral and bacterial pharyngeal swab tests did not reveal any pathological findings. A 157 
further diagnostic work-up for tropical diseases was requested and serum and urine samples 158 
(taken 5, 8 and 18 days after start of symptoms) were sent to the Reference Laboratory, 159 
Cantacuzino Institute in Bucharest. NS1 dengue antigen was negative, ELISA testing 160 
(Euroimmune, Lübeck, DE) for Zika IgM antibodies showed borderline values on the first two 161 
samples (index value 0.901 [(negative< 0.8, positive >1.1]) with seroconversion by day 18 of 162 
illness (index value = 2.02). ELISA for Zika IgG antibodies was negative in the first two (index 163 
= 0.1) and borderline positive in the last serum samples (index = 1.064). Real time PCR (in-164 
house test) was positive for ZIKV RNA in the urine samples taken 5 and 8 days after 165 
symptom onset but negative in the serum samples taken at the same time. Symptomatic 166 
treatment was recommended and counselling was provided regarding sexual transmission 167 
and the need to avoid pregnancy for 6 months for his partner. The rash disappeared after 3 168 
days, his platelet count normalized in one week and no other signs and symptoms appeared 169 
during the 6-month follow-up. His wife was not tested for Zika virus infection and did not 170 
develop clinical illness, but avoided pregnancy for 6 months.  171 
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Discussion 172 
Arboviruses are found worldwide and more than 150 are documented to cause disease in 173 
humans (1, 5). Overall, vector-borne diseases imported to Europe through travel are 174 
increasing, among them arbovirus infections such as dengue and chikungunya (2). The 175 
clinical presentation of an acute arbovirus infection can range from asymptomatic or mild 176 
disease, up to severe life-threatening courses and death, with a high disease burden in 177 
endemic countries. Due to the broad spectrum of differential diagnoses, a rapid and targeted 178 
diagnostic approach is necessary. 179 
The clinical syndromes of arbovirus disease can generally be divided in four main syndromes 180 
consisting of (1) fever alone or fever with (2) rash and arthralgia, (3) neurological symptoms 181 
and/or (4) haemorrhagic symptoms (1). Most arboviruses are associated with one or more 182 
than one of these syndrome complexes, with fever as a common feature for all of them, with 183 
the exception of Zika, where fever is not always present (33, 34). However, there is 184 
significant overlap between the syndromic groups [Fig 2]. Most arboviruses cause a biphasic 185 
illness with initial non-specific symptoms for a few days followed by improvement then either 186 
resolution or more severe features starting about a week after symptom onset. Common 187 
laboratory features of all three arboviruses are decreased white cell counts and platelet 188 
counts, less pronounced in Zika virus infection. For a comparison of clinical and laboratory 189 
findings in chikungunya, dengue and Zika virus infections, see Tables 1 and 2. 190 
 191 
Chikungunya infection (Case 1) is usually associated with abrupt onset of fever and malaise 192 
after an incubation period of 3-7 days, although this can extend to 12 days. Most (more than 193 
75%) infected patients develop symptoms (21). Distinction from dengue may be difficult, 194 
especially in travellers returning from areas where both infections are circulating (35). Typical 195 
symptoms include fever that can exceed 39°C and pol yarthralgia. Symmetrical bilateral 196 
arthralgia is found in most patients and is usually located in the peripheral joints, appearing 197 
shortly after the onset of fever (2-5 days). There may also be visible or palpable swelling. A 198 
macular or maculopapular rash is commonly seen, in up to 75% of patients. Other symptoms 199 
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include pruritus, conjunctivitis, headache, myalgia and gastrointestinal symptoms (36, 37). 200 
Laboratory abnormalities that are commonly seen in chikungunya infection include 201 
lymphopenia, thrombocytopenia and elevated aminotransferase levels (36, 37). 202 
The viraemic period can range from 2-10 days with a total duration of acute illness around 7 203 
to 10 days. Some patients experience persistence of relapse of arthralgia for months with the 204 
risk of developing chronic joint symptoms or even chronic inflammatory polyarthralgia (38, 205 
39). Alopecia and depression are also reported as long-term sequelae (40). 206 
 207 
Dengue virus infection (Case 2) is classified by the WHO in the following categories: dengue 208 
without warning signs, dengue with warning signs and severe dengue (41). During the 209 
course of disease, three phases can be seen that consist of a febrile phase, a critical phase 210 
and a recovery phase (41). Travellers are usually seen in the febrile phase, which lasts about 211 
2-7 days. Patients present with high fever accompanied by headache, vomiting, myalgia, 212 
arthralgia and a transient blanching discrete or coalescent macular rash. This rash often has 213 
"islands of white in a sea of red" (5). Pruritus may be present initially. Severe headache, pain 214 
behind the eyes, back pain, and myalgia and arthralgia are reported in up to 70% of cases 215 
(42), with rash in around 50%. Other symptoms may include gastrointestinal manifestations 216 
such as diarrhoea, vomiting, pain and nausea and symptoms resembling a respiratory tract 217 
infection (cough, running nose, sore throat, injected pharynx). Mild haemorrhagic 218 
manifestations like petechiae and mucosal membrane bleeding from gum or nose can occur 219 
(41). In this phase, clinical features are indistinguishable between severe and non-severe 220 
dengue and are also difficult to distinguish from other non-dengue febrile illnesses. The 221 
tourniquet (Hess) test is advocated to identify severe disease early: a blood pressure cuff is 222 
inflated to between systolic and diastolic pressure for 5 minutes and the resulting petechiae 223 
are counted. However, the specificity and sensitivity of this test is moderate (43). Laboratory 224 
abnormalities include a decreased white blood count, particularly neutropenia. The febrile 225 
phase may followed by defervescence around day 3-7 of illness and is characterized by 226 
increase capillary permeability and in severe illness bleeding and significant plasma leakage. 227 
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Laboratory findings in this phase include increased haematocrit, thrombocytopenia and 228 
leukopenia, particularly neutropenia. The risk of having complications and progressing to 229 
severe dengue is highest in this phase. The recovery phase that follows is characterized by 230 
fluid resorption and gradual recovery. 231 
 232 
In Zika infection (Case 3), symptoms are the most non-specific of all three viruses and 233 
differential diagnosis remains a challenge. A large proportion of infections remain 234 
asymptomatic and only 20-25% of infected individuals present with symptoms (44). 235 
Acute Zika virus infection is usually characterized by low-grade fever (up to 38.5°C), rash, 236 
arthralgia and conjunctivitis. Other symptoms include myalgia, headache, eye pain and 237 
asthenia (45, 46). A maculopapular rash is seen in around 90% of patients, but fever is less 238 
pronounced and less common than in chikungunya and dengue infections, affecting 40-75% 239 
of patients and thrombocytopenia is also much less common. As highlighted in case 3, 240 
asymptomatic infections have to be considered in case pregnancy is planned after travel of 241 
the patient or their partner to an endemic area. Current recommendations do not recommend 242 
testing of asymptomatic returning travellers; therefore emphasis should be put on pre-travel 243 
advice for couples that are planning a pregnancy (47, 48). 244 
In the diagnostic approach for the three arboviruses presented here, both serology and direct 245 
virus demonstration (such as PCR testing) are useful but several characteristics of the 246 
viruses influence time and cost-effective diagnostic work-up. Serological testing includes 247 
detection of IgG and IgM antibodies that are usually present by a week after onset of 248 
symptoms of all three viruses. Dengue virus and Zika virus are both flaviviruses, so cross-249 
reactivity of antibodies may be problematic. Positive antibody findings may be due to acute 250 
infection, but could also result from previous infection with the same or another flavivirus, or 251 
following previous immunization against yellow fever or tick-borne encephalitis (49). This 252 
cross-reactivity can complicate the interpretation of results, and previous exposure history 253 
and immunization history should be checked and the information should be delivered to the 254 
laboratory. Frequent travellers who have received immunizations against yellow fever, 255 
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Japanese encephalitis or tick-borne encephalitis can show a considerable antibody 256 
background for flaviviruses that can mimic a wild-type flavivirus infection. 257 
Direct virus detection by PCR is another option for diagnosing flaviviruses, which is highly 258 
specific when positive. However, the duration of viraemia in flavivirus infections is short and 259 
therefore PCR test positivity is confined to the first few days of illness. This window is often 260 
missed in returning travellers, especially if their symptoms start while still abroad. For 261 
dengue, direct detection of the virus antigen NS-1 in blood that can prolong the window up to 262 
7 days (41). Of wider interest, it has recently been shown that detection of virus RNA in urine 263 
can prolong the window for PCR diagnosis for up to several weeks after onset of symptoms 264 
of dengue and other arboviruses (50-52). Diagnostic testing for other, more rare arboviruses 265 
beyond the three common ones presented here is mostly limited to specialized laboratories. 266 
 267 
Conclusion 268 
The identification and diagnosis of acute arbovirus infections can be challenging and 269 
laborious for both physicians and clinical virologists, although the combination of 270 
epidemiology, clinical syndromes and findings in basic blood tests such as the blood count 271 
may provide useful clues. As arboviruses are an emerging group of viruses in Europe and 272 
beyond and access to highly specified diagnostics is often limited, recognition of suspected 273 
arbovirus infections should be addressed both in clinical training as well as in research on 274 
diagnostics and therapeutics. 275 
  276 
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Figure legends 455 
Figure 1. 456 
Blanching rash of dengue fever in a returning traveller. 457 
 458 
Figure 2. 459 
Summary of arbovirus syndromes together with fever: Central nervous system; Fever 460 
arthralgia rash; Viral haemorrhagic fever. (a) alphavirus; (c) coltivirus; (f) flavivirus;(b) 461 
bunyavirus; (n) nairovirus; (p) phlebovirus. CCHF Crimean Congo haemorrhagic fever; CHIK 462 
chikungunya; CTFV Colorado tick fever; DEN dengue; EEEV Eastern equine encephalitis; JE 463 
Japanese encephalitis; LACV La Crosse virus; MVEV Murray Valley encephalitis; ONNV 464 
O’nyong nyong; RRV Ross River fever; RVFV Rift Valley fever; SLEV St Louis encephalitis; 465 
TBEV tick borne encephalitis; VEEV Venezuelan encephalitis; WEEV Western equine 466 
encephalitis; WNV West Nile fever; YFV yellow fever; ZIKV Zika virus. Adapted (with 467 
permission) from Solomon T, Chapter 40 in eds Beeching N, Gill G, Lecture Notes Tropical 468 
Medicine, Wiley 2014; p 274. 469 
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Table 1. Comparison of selected clinical findings in chikyungunya, dengue and Zika 471 
infections 472 
Clinical presentation Chikungunya Dengue Zika 
Fever +++ +++ + 
Rash ++ ++ +++ 
Myalgia + +++ + 
Arthralgia +++ + ++ 
Oedema - - ++ 
Retro-orbital pain + ++ + 
Conjunctivitis +++ - +++ 
Lymphadenopathy ++ ++ + 
Hepatomegaly +++ - - 
Haemorrhage - + - 
+++ (very common), ++ (frequently observed), + (sometimes observed), - (no typical 473 
symptom) 474 
Table adapted and modified from (33, 53). 475 
  476 
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Table 2. Comparison of baseline laboratory findings in chikyungunya, dengue and Zika 477 
infections 478 
Laboratory findings Chikungunya Dengue Zika 
Anaemia + - - 
Leucopenia ++ +++ -/+ 
Neutropenia + +++ - 
Lymphocytopenia +++ ++ -/+ 
Thrombocytopenia + +++ -/+* 
Increased CRP ++ +++ - 
Increased ALT ++ +++ - 
+++ (very common) ++ (frequently observed), + (sometimes observed), - (no typical 479 
symptom); *if observed, thrombocytopenia is only mild. 480 
Table adapted and modified from (33), additional data from (54, 55). 481 
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